ENTA
Enanta Pharmaceuticals Inc
12.10$
-2.2%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.3% | -3.5% | -3.6% | -5.6% | -7.4% | -7.4% | -6.8% | -6.7% | +17.4% | -4.5% | -5.7% | |
| – | -7.7% | -10.1% | -18.4% | +4.6% | -10.6% | -9.4% | -8.3% | -8.2% | -2.8% | -10.2% | +14.1% | |
| – | -53.2% | +59.1% | -43.7% | +4.1% | +126.5% | -28.6% | -25.6% | -27.9% | +15.9% | -6.7% | -4.3% | |
| – | -8.9% | -10.9% | -23.4% | +7.9% | -12.7% | -10.8% | +5.6% | -7.5% | -1.6% | -11.9% | +15.7% | |
| – | +0.7% | -0.3% | +2.1% | -4.9% | +3.9% | +1.2% | -79.4% | -17.6% | +23.4% | -7.8% | -16.5% | |
| – | – | +0.0% | +0.0% | – | – | – | – | – | – | – | – | |
| – | -3.6% | +4.6% | +1.0% | -0.8% | -4.4% | -3.1% | -3.4% | -2.6% | -6.1% | -2.4% | -1.2% | |
| – | -0.6% | -12.5% | +6.6% | -1.2% | -14.7% | -6.3% | -3.0% | +9.0% | -7.9% | +3.8% | +16.6% | |
| – | +15.1% | -19.8% | -6.8% | +3.6% | -6.2% | -2.6% | -8.3% | +12.3% | +4.2% | -0.1% | -88.9% | |
| – | +127.6% | -27.9% | +58.7% | -25.0% | -40.9% | +0.6% | -25.4% | -45.1% | -3.2% | +131.5% | -24.5% | |
| – | -11.5% | -13.4% | -10.4% | -13.5% | -13.2% | -16.3% | -15.2% | -18.4% | +95.6% | -7.9% | -13.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.4% | +0.1% | +0.0% | +0.2% | +0.6% | -0.2% | +0.3% | +34.5% | +1.0% | +0.2% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.